Evaluating Physician-AI Interaction for Cancer Management: Paving the Path towards Precision Oncology
Authors:
Zeshan Hussain,
Barbara D. Lam,
Fernando A. Acosta-Perez,
Irbaz Bin Riaz,
Maia Jacobs,
Andrew J. Yee,
David Sontag
Abstract:
We evaluated how clinicians approach clinical decision-making when given findings from both randomized controlled trials (RCTs) and machine learning (ML) models. To do so, we designed a clinical decision support system (CDSS) that displays survival curves and adverse event information from a synthetic RCT and ML model for 12 patients with multiple myeloma. We conducted an interventional study in a…
▽ More
We evaluated how clinicians approach clinical decision-making when given findings from both randomized controlled trials (RCTs) and machine learning (ML) models. To do so, we designed a clinical decision support system (CDSS) that displays survival curves and adverse event information from a synthetic RCT and ML model for 12 patients with multiple myeloma. We conducted an interventional study in a simulated setting to evaluate how clinicians synthesized the available data to make treatment decisions. Participants were invited to participate in a follow-up interview to discuss their choices in an open-ended format. When ML model results were concordant with RCT results, physicians had increased confidence in treatment choice compared to when they were given RCT results alone. When ML model results were discordant with RCT results, the majority of physicians followed the ML model recommendation in their treatment selection. Perceived reliability of the ML model was consistently higher after physicians were provided with data on how it was trained and validated. Follow-up interviews revealed four major themes: (1) variability in what variables participants used for decision-making, (2) perceived advantages to an ML model over RCT data, (3) uncertainty around decision-making when the ML model quality was poor, and (4) perception that this type of study is an important thought exercise for clinicians. Overall, ML-based CDSSs have the potential to change treatment decisions in cancer management. However, meticulous development and validation of these systems as well as clinician training are required before deployment.
△ Less
Submitted 23 April, 2024;
originally announced April 2024.
